Charles W. Newton net worth and biography

Charles Newton Biography and Net Worth

Director of Keros Therapeutics

Charles Newton has served as a member of our board of directors since March 2026. Mr. Newton was most recently the Chief Financial Officer of Lyell Immunopharma, Inc. Previously, Mr. Newton served as Managing Director & Co-Head of Healthcare Investment Banking in the Americas at Bank of America. Earlier in his career, he served as Managing Director and Co-Head of Healthcare Investment Banking in the Americas at Credit Suisse, Managing Director and Head of Western Region Healthcare Investment Banking at Morgan Stanley and as a Corporate Finance Analyst at Lehman Brothers. Mr. Newton currently serves as a board member at Novavax, Inc. and Coherus Oncology, Inc. Mr. Newton received an M.B.A. from The Tuck School at Dartmouth College and a B.S. in Finance from Miami University.

What is Charles W. Newton's net worth?: The estimated net worth of Charles W. Newton is at least $135.34 thousand as of June 11th, 2026. Mr. Newton owns 12,665 shares of Keros Therapeutics stock worth more than $135,338 as of July 17th. This net worth approximation does not reflect any other investments that Mr. Newton may own. Learn More about Charles W. Newton's net worth.
How do I contact Charles W. Newton?: The corporate mailing address for Mr. Newton and other Keros Therapeutics executives is 99 HAYDEN AVENUE SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER, LEXINGTON MA, 02421. Keros Therapeutics can also be reached via phone at 617-314-6297 and via email at [email protected]. Learn More on Charles W. Newton's contact information.
Has Charles W. Newton been buying or selling shares of Keros Therapeutics?: Charles W. Newton has not been actively trading shares of Keros Therapeutics in the last ninety days. Most recently, Charles W. Newton sold 550 shares of the business's stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $10.04, for a transaction totalling $5,522.00. Following the completion of the sale, the director now directly owns 12,665 shares of the company's stock, valued at $127,156.60. Learn More on Charles W. Newton's trading history.
Who are Keros Therapeutics' active insiders?: Keros Therapeutics' insider roster includes Carl Gordon (Director), Carl Gordon (Director), Julius Knowles (Director), Jennifer Lachey (Insider), Charles Newton (Director), Keith Regnante (CFO), and Alpna Seth (Director). Learn More on Keros Therapeutics' active insiders.
Are insiders buying or selling shares of Keros Therapeutics?: During the last year, Keros Therapeutics insiders bought shares 2 times. They purchased a total of 2,000 shares worth more than $21,890.00. During the last year, insiders at the sold shares 6 times. They sold a total of 10,185,020 shares worth more than $180,724,555.75. The most recent insider tranaction occured on June, 15th when Director Jean Jacques Bienaime bought 1,000 shares worth more than $10,190.00. Insiders at Keros Therapeutics own 12.6% of the company. Learn More about insider trades at Keros Therapeutics.
Information on this page was last updated on 6/15/2026.

Charles W. Newton Insider Trading History at Keros Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/11/2026	Sell	550	$10.04	$5,522.00	12,665

Charles W. Newton Buying and Selling Activity at Keros Therapeutics

Keros Therapeutics Company Overview

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Today's Range

Now: $10.59

$10.37

$10.76

50 Day Range

MA: $10.90

$9.91

$12.07

2 Week Range

Now: $10.59

$9.69

$22.55

Volume

56,160 shs

Average Volume

362,882 shs

Market Capitalization

$209.48 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.97